Latest Breaking News On - Enrique conterno - Page 9 : comparemela.com
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac s COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
FibroGen to Present at Upcoming Investor Conferences
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
FibroGen Inc (FGEN) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble.
FibroGen Inc (NASDAQ: FGEN)
Operator
Good day, and welcome. Thank you for standing by. Welcome to the FibroGen First Quarter 2021 Financial Results Conference Call. [Operator Instructions] After the speakers presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to hand the conference over to your speaker for today, Mr. Michael Tung. Please go ahead.SPONSORED:
10 stocks we like better than FibroGen
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade,
FibroGen, Inc. (NASDAQ: FGEN) Securities Fraud Action:
The complaint centers on FibroGen s presentation of false data of roxadustat to make the anemia drug look safer than it is.
Throughout the Class Period, FibroGen touted the prospects of roxadustat. A key selling point for the drug was its purported heart safety as compared to standard of care erythropoietin (EPO) injectable therapies, which cannot be proscribed to a variety of patients at risk of major cardiac events. To support this marketing edge, FibroGen presented data from phase 3 trials purportedly showing roxadustat was safer than EPO, among other at risk populations, in incident dialysis patients.